PhD Scientific Days 2026

Poster Session 3.J - Theoretical and Translational Medicine

Exploring Anti-tumor Effect of GSK3β Inhibitor Elraglusib (9-ING-41) on Cancer: Systematic Review of In vivo Studies

Name of the presenter

Ahmed, Ebsa Tofik

Institute/workplace of the presenter

Clinical Pathophysiology

Authors

Ebsa Tofik Ahmed¹, Csaba Andras Schvarcz, Qusay O. Abdalla, Evan Santo, Daniel Bosci, Zoltan Koos, Hakim Bahlok Jebur, Mohamed I . Elsalahaty, Mingming He, Yibo Gu, Cedrik Kintscher, Peter Hamar¹
1: Semmelweis University

Text of the abstract

Background
Glycogen synthase kinase-3β (GSK3β) plays an important role in the pathogenesis of different types of cancer. Therefore, it is becoming an emerging therapeutic target in many types of cancer. Even though there are many small molecule inhibitors designed against GSK3β, lack of selectivity to GSK3β prevented many promising GSK3β inhibitors from progress in clinical trial phases. Several studies reported 9-ING-41 as a novel and more selective inhibitor of GSK3β in different types of cancer.
Aim
To explore the in vivo antitumor effect of 9-ING-41 either alone or in combination with other drugs on different types of cancer from published studies.
Methods
A systematic literature search was performed in Embase, Pubmed, Scopus and Web of Science databases for papers published during 10 years prior to April 2026. All in vivo studies assessing the anti-tumor effect of 9-ING-41 on different tumor models were included. The primary outcomes such as tumor volume and tumor weight were included. Quality assessment and narrative synthesis of the studies were performed.
Results
Seven studies met eligibility criteria for inclusion out of the 212 papers that were initially identified. Only one included study using the breast cancer tumor model (BC-2 PDX) showed a significant reduction in tumor volume and tumor weight when using the 9-ING-41 therapy alone. However, 9-ING-41 in combination with chemotherapeutic drugs, immune checkpoint inhibitor, and oncolytic adenovirus significantly reduced tumor volume and tumor weight in tumor models such as pancreatic (PCF379419, 6741 PDX), breast (BC-1 PDX, BC-2 PDX), glioblastoma (GBM6 PDX), and neuroblastoma (SK-N-BE, SK-N-DZ) in four included studies.
Conclusion
The 9-ING-41 showed better antitumor effect when used in combination with other therapeutic agents such as chemotherapeutic drugs, immune checkpoint inhibitor and oncolytic adenovirus than when it used alone. Therefore, this review may serve as a baseline line for future research on combination of 9-ING-41 with other therapeutic agents like adjuvant or supplementary therapy in other cancer models.
Funding : SE 250+ Excellence PhD Scholarship
Email: ebsa.ahmed@phd.semmelweis.hu
University: Semmelweis University
Supervisor: Prof. Dr. Peter Hamar
Presentation: Poster Presentation